Skip Navigation



Annals of Oncology Advance Access published online on April 26, 2005
Annals of Oncology, doi:10.1093/annonc/mdi193
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/6/869    most recent
mdi193v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kalofonos, H.P.
Right arrow Articles by Fountzilas, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kalofonos, H.P.
Right arrow Articles by Fountzilas, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received December 20, 2004
Revised February 1, 2005
Accepted February 14, 2005

Original article

Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study

H.P. Kalofonos 1*, G. Aravantinos 2, P. Kosmidis 3, P. Papakostas 4, T. Economopoulos 5, M. Dimopoulos 6, D. Skarlos 7, A. Bamias 8, D. Pectasides 5, S. Chalkidou 9, M. Karina 10, A. Koutras 1, E. Samantas 2, C. Bacoyiannis 3, G.F. Samelis 4, G. Basdanis 10, F. Kalfarentzos 1, and G. Fountzilas 10

1 Patras University Hospital,Patras, Greece;
2 Third Department of Medical Oncology, Agii Anargiri Cancer Hospital, Greece;
3 HYGEIA Medical Center, Athens, Greece;
4 Oncology Unit, Hippokratio General Hospital of Athens, Greece;
5 Attikon University Hospital, Athens, Greece;
6 Alexandra Hospital, Department of Clinical Therapeutics, University of Athens School of Medicine, Greece;
7 Oncology Department, Henry Dunan Hospital, Athens, Greece;
8 Oncology Department, University Hospital of Ionnina, Greece;
9 HeCOG Data Office, Athens, Greece;
10 ‘Papageorgiou’ Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece

* To whom correspondence should be addressed.
H.P. Kalofonos, E-mail: kalofon{at}med.upatras.gr


  Abstract

Background: Irinotecan (IRI) and oxaliplatin (OXA) are effective in the treatment of colorectal cancer. Previously untreated patients with advanced colorectal carcinoma (CRC) were randomly assigned to receive IRI plus leucovorin (LV)/5-fluorouracil (5-FU), or OXA plus LV/5-FU in order to compare the response rates, time-to-tumor progression, overall survival rates, and toxicity profiles of these two agents.

Materials and methods: From January 1999 to February 2002, 295 patients were randomized to receive either IRI/LV/5-FU or OXA/LV/5-FU. The treatment schedules consisted of weekly IRI 70 mg/m2 or OXA 45 mg/m2 plus LV 200 mg/m2 followed immediately by intravenous bolus 5-FU 450 mg/m2 for 6 weeks, followed by a 2-week rest period. Treatment was continued for up to four cycles or until disease progression, unacceptable toxicity or patient refusal.

Results: There were no significant differences between the study arms in the overall response rate (33% with IRI/LV/5-FU versus 32% with OXA/LV/5-FU based on responses demonstrated on a single evaluation; 23% with IRI/LV/5-FU versus 22.3% with OXA/LV/5-FU based on responses confirmed according to WHO criteria) median time to progression (8.9 versus 7.6 months), and median overall survival (17.6 versus 17.4 months). Toxicity profiles (grades 3 and 4) were similar in the IRI and OXA arms (diarrhea 12.3% and 9.8%, neutropenia 8.2% and 4.9%, and febrile neutropenia 1.4% and 1.4%, respectively), with the exception of grade 3 sensory neuropathy, which almost exclusively occurred in the OXA arm (0% versus 5.6%; P=0.003, Fisher's exact test).

Conclusion: The IRI/LV/5-FU and OXA/LV/5-FU regimens demonstrated equally substantial efficacies and manageable toxicity profiles in the first-line treatment of patients with advanced CRC. However, IRI/LV/5-FU may be the preferable regimen to avoid significant neurotoxicity associated with OXA-LV/5-FU.

Keywords: colorectal cancer; chemotherapy; irinotecan; oxaliplatin.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NeurologyHome page
A. A. Argyriou, E. Chroni, P. Polychronopoulos, G. Iconomou, A. Koutras, T. Makatsoris, M. K. Gerolymos, P. Gourzis, K. Assimakopoulos, and H. P. Kalofonos
Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy
Neurology, December 26, 2006; 67(12): 2253 - 2255.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Meyerhardt, A. X. Zhu, P. C. Enzinger, D. P. Ryan, J. W. Clark, M. H. Kulke, C. C. Earle, M. Vincitore, A. Michelini, S. Sheehan, et al.
Phase II Study of Capecitabine, Oxaliplatin, and Erlotinib in Previously Treated Patients With Metastastic Colorectal Cancer
J. Clin. Oncol., April 20, 2006; 24(12): 1892 - 1897.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. A. P. Hospers, M. Schaapveld, J. W. R. Nortier, J. Wils, A. van Bochove, R. S. de Jong, G. J. Creemers, Z. Erjavec, D. J. de Gooyer, P. H. Th. J. Slee, et al.
Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer
Ann. Onc., March 1, 2006; 17(3): 443 - 449.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. J. A. Punt
Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?
Ann. Onc., June 1, 2005; 16(6): 845 - 846.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.